Loading
INV-1120 is an experimental EP4 antagonist from Shenzhen Ionova Life Sciences, in phase 1 trials for advanced solid tumours.
INV-1120 is an EP4 antagonist from Shenzhen Ionova Life Sciences. An EP4 inhibitor (antagonist) tested alone and with pembrolizumab in advanced solid tumours. Its furthest stage is phase 1, for advanced solid tumours. ClinicalTrials.gov registers it in one study linked below. Registry status RECRUITING (phase 1) on 3 Nov 2026; the company's latest INV-1120 news is from Nov 2022. Whether it works in people has not been established unless a trial below reports it.
An EP4 inhibitor (antagonist) tested alone and with pembrolizumab in advanced solid tumours. Connects to EP4 (PTGER4).
1.INV-1120 slips into a pocket on EP4 (PTGER4).
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"INV-1120" OR ABSTRACT:"INV-1120") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about INV-1120, not a curated reading list.
Shares EP4 (PTGER4), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Shenzhen Ionova Life Sciences and the tag pipeline.
Shares Shenzhen Ionova Life Sciences and the tag pipeline.
Shares Shenzhen Ionova Life Sciences and the tag pipeline.
Shares Shenzhen Ionova Life Sciences and the tag pipeline.
Shares Shenzhen Ionova Life Sciences and the tag pipeline.
Shares Shenzhen Ionova Life Sciences and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/